Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER".

Niamh M KeeganSimon J FurneyJanice M WalsheGiuseppe GulloM John KennedyDiarmuid SmithJohn McCaffreyCatherine M KellyKeith EganJennifer KerrMark GivenPeter O'DonovanAndres HernandoAusra TeiserskieneImelda ParkerElaine KayAngela FarrellyAoife CarrGiulio CalzaferriRay McDermottMaccon M KeaneLiam GroganOscar BreathnachPatrick G MorrisSinead ToomeyBryan T Hennessy

Published in: Cancers (2021)

Copanlisib and trastuzumab can be safely administered with fair overall tolerability. Preliminary evidence of tumour stability was observed in patients with heavily pre-treated, metastatic HER2 positive breast cancer. Several potential biomarkers were identified for further study in the current phase 2 clinical trial. NCT: 02705859.

Keyphrases

positive breast cancer
clinical trial
open label
phase ii
epidermal growth factor receptor
phase iii
study protocol
small cell lung cancer
metastatic breast cancer
squamous cell carcinoma
double blind
randomized controlled trial
newly diagnosed
protein kinase